Cureus
September 1, 2023
Nm Mahmudul Alam Bhuiya, Robin J Jacobs, Karina Wang et al.
3 citations
Background Psilocybin has been studied for its potential therapeutic benefits, particularly for the treatment of psychiatric disorders such as anxiety, depression, and obsessive-compulsive disorder. While more research is needed as psilocybin-assisted therapy becomes more prevalent, future pharmacists will probably be involved at some level. At present, pharmacists receive minimal training on...
Psycho-Oncology
August 16, 2023
Puttichai Tungtong, Adelita V Ranchor, Maya J. Schroevers
Objective: Cancer patients are at an increased risk for affective problems, including feelings of anxiety and depression. Mindfulness has been linked to an array of benefits for affective functioning in various populations including cancer patients, but the mechanisms underlying this relationship are still poorly understood. Based on emotion-regulation and stress-coping models, this study...
Journal of Education, Health and Sport
August 15, 2023
Justyna Woźniak, Rafał Bogacz, Magdalena Gaik et al.
Introduction: The word “psychedelic” derives from the Greek language and can be loosely translated as “mind manifesting” which is to convey that these substances allow the mind to unleash its hidden potential. Psilocybin is considered to be a “classic psychedelic” and is most commonly found in the form of so-called “magic mushrooms”. Due to its unique properties psilocybin has been used during...
Child Psychiatry and Human Development
August 2023
Nathaniel A. Shanok, Camila Saldias-Manieu, Krystal D. Mize et al.
Mindfulness meditation is a means of increasing awareness of the present moment. Mindfulness Mediation Interventions (MMI) positively impact psychological functioning, yet the neurocognitive mechanisms that mediate these effects have been less well-defined. Here, the primary aim was to evaluate whether the effects of a 10-week MMI were mediated by changes in attention and creativity...
eNeuro
August 2023
Jenessa N Johnston, Josh Allen, Irene Shkolnikov et al.
Over the past decade, ketamine, an NMDA receptor antagonist, has demonstrated fast-acting antidepressant effects previously unseen with monoaminergic-based therapeutics. Concerns regarding psychotomimetic effects limit the use of ketamine for certain patient populations. Reelin, an extracellular matrix glycoprotein, has shown promise as a putative fast-acting antidepressant in a model of...
Cureus
August 1, 2023
Jonathann Kuo, Tabitha Block, Megan Nicklay et al.
2 citations
Mental health disorders are among the most common health conditions in the United States. Traditional clinical treatments rely on psychiatric counseling and, in many cases, prescription medications. We propose an innovative model, Interventional Mental Health, which employs a combination of modalities through a multifaceted approach to treat conditions that have exhibited limited responsiveness...
International Journal of Drug Policy
August 1, 2023
Tayler Holborn, Fabrizio Schifano, Paolo Deluca
15 citations
The proliferation of Novel Psychoactive Substances (NPS) presents a challenge for global drug policy. The ease of online drug purchase and the emergence of the dark web have created new avenues for the growth of NPS. Despite the global nature of this issue, limited research has examined motivations of use. These include perceived safety or convenience, an interest in novel pharmacology and...
Sleep Medicine
August 1, 2023
David A Kalmbach, Philip Cheng, Anthony N Reffi et al.
15 citations
Cognitive-behavioral therapy is effective for prenatal insomnia, but unresolved cognitive arousal limits patient outcomes. Therapies aimed at reducing cognitive arousal may benefit pregnant women with insomnia. This proof-of-concept trial evaluated Perinatal Understanding of Mindful Awareness for Sleep (PUMAS, which combines mindfulness with behavioral sleep strategies) on insomnia, depression,...
Journal of Affective Disorders
August 1, 2023
Richard J. Zeifman, Anne C Wagner, Candice M Monson et al.
56 citations
Psilocybin therapy is receiving attention as a mental health intervention with transdiagnostic potential. In line with psychotherapeutic research, qualitative research has highlighted the role of reductions in experiential avoidance (and increases in connectedness) within psilocybin therapy. However, no quantitative research has examined experiential avoidance as a mechanism underlying...
Journal of community genetics
July 17, 2023
Sarah Velissaris, Marie‐Claire Davis, Fiona Fisher et al.
People with Huntington's disease (HD) face difficult emotional and practical challenges throughout their illness, including in the pre-symptomatic stage. There are, however, extremely limited psychosocial interventions adapted to or researched for HD. We adapted and piloted an 8-week mindfulness-based stress reduction (MBSR) program in people with pre-symptomatic HD to determine if the program...